Trial Profile
To evaluate WLL followed by inhaled GM-CSF (sargramostim) as therapy for moderate to severe autoimmune pulmonary alveolar proteinosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Therapeutic Use
- 01 Dec 2023 New trial record
- 30 Nov 2023 According to a Partner Therapeutics Media Release, results from this study published in the European Respiratory Journal.
- 30 Nov 2023 Results presented in a Partner Therapeutics Media Release.